30 closest matches · ranked by relevance
Non Small Cell Lung Cancer With Bone Metastatses
Primary: Number of Symptomatic Skeletal Events (SSE) in Patients Receiving Xofigo With NSCLC and Bone Metastases — 1 Number of participants experiencing SSE
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Non-Small-Cell Lung Cancer
Primary: Progression-Free Survival — 9.0; 11.3 Months
Lung Cancer, Non-Small Cell
Primary: Overall Survival — 4.0; 3.6 months — p=0.1862
Small Cell Lung Cancer · Extensive Stage Lung Cancer · Chemonaive
Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants
Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) — 10.9; 10.7 months — p=0.5157
Non-small Cell Lung Cancer · Brain Cancer
Primary: Median Survival — 11.8 months
Lung Cancer · Metastatic Cancer
Primary: Number of Patients With Intracranial Response — 3 participants
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants
Lung Cancer
Primary: Boost Dose Toxicity — 5 Participants
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
Primary: Objective Response Rate — 0; 1 participants
Non Small Cell Lung Cancer
Primary: Overall Survival — 26.81; 24.97 months — p=0.831
Non-Small Cell Lung Cancer
Primary: Survival Without Grade 3 or 4 Toxicity — 3.2; 0.7 months — p=<0.001
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Lung Cancer
Primary: 6 Month Progression-Free Survival — 69 percentage of participants
Extensive Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: Objective Response (Confirmed and Unconfirmed, Complete and Partial Responses Per RECIST) — 11; 2 percentage of participants
Stage IV Non-Small Cell Lung Cancer
Primary: Progression Free Survival — 3.5; 9.7 months — p=.01
Lung Cancer
Primary: 18 Month Survival — 58; 54 percentage of participants
Lung Cancer
Primary: Mediastinal Nodal Clearance After Completion of Induction Chemoradiotherapy With or Without Panitumumab. — 68.2; 48.7 percentage of participants — p=0.96
Lung Cancer
Primary: Overall Survival (12-month Rate Reported) — 60.1; 50.8 percentage of participants — p=0.2103
Non-Small-Cell Lung Cancer
Primary: Time to Progression — 3.12; 1.64 months
Non-Small Cell Lung Cancer
Primary: Duration of Treatment of Anti-cancer Drugs — 11; 14; 9.4; 15.8 Months
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 9.4 Weeks
Non-Small-Cell Lung Cancer
Primary: Percentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate) — 52.8; 39.3 percentage
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 8.5 months
Lung Cancer
Primary: Overall Response Rate — 65; 50 percentage of participants
Lung Cancer
Primary: Number of Grade 3/4 Toxicities Patients Experienced on Maintenance Bevacizumab Following Chemoradiation for Limited Stage - Small Cell Lung Cancer (LS-SCLC) — 2; 1; 1; 1…
Extensive Stage Lung Small Cell Carcinoma · Recurrent Lung Small Cell Carcinoma
Primary: Progression-free Survival (PFS) — 5.5; 4.9 months — p=0.17
Non Small Cell Lung Cancer
Primary: Overall Survival Time (OS) — 11.5; 9.9 Months — p=0.0120
Non-small Cell Lung Cancer
Primary: Progression Free Survival — 9.7; 4.2 months